Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Lopez

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2020
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
European Journal of Pediatrics|June 12, 2026
International variation in child healthcare practices and implications for childhood cancer diagnosis: a scoping review and cross-country clinician surveyAngela Lopez-Cortes, Aisha Al-Mahdy, Zsuzsanna Jakab, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pediatric Blood & Cancer|August 9, 2024
Multimodality detection of tumour rupture in children with Wilms tumourKristina Dzhuma, Minou Oostveen, Tom Watson, et al.
JAMA Network Open|February 9, 2026
Stage at Diagnosis and International Survival Variation in Childhood Tumors in the BENCHISTA StudyLaura Botta, Fabio Didonè, Angela Lopez-Cortes, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Journal of Clinical Medicine|January 21, 2022
Unraveling Bicuspid Aortic Valve Enigmas by Multimodality Imaging: Clinical ImplicationsArturo Evangelista Masip, Laura Galian-Gay, Andrea Guala, et al.
BMJ Open|June 15, 2019
Three contaminated sites in southern Italy. The Neonatal Environment and Health Outcomes cohort: protocol for a longitudinal birth cohort studySilvia Ruggieri, Gaspare Drago, Paolo Colombo, et al.
Iscience|August 18, 2025
A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancerShusuan Jiang, Ye Tian, Hongqian Guo, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 9, 2020
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN studyHirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
European Journal of Pediatrics|June 12, 2026
International variation in child healthcare practices and implications for childhood cancer diagnosis: a scoping review and cross-country clinician surveyAngela Lopez-Cortes, Aisha Al-Mahdy, Zsuzsanna Jakab, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pediatric Blood & Cancer|August 9, 2024
Multimodality detection of tumour rupture in children with Wilms tumourKristina Dzhuma, Minou Oostveen, Tom Watson, et al.
JAMA Network Open|February 9, 2026
Stage at Diagnosis and International Survival Variation in Childhood Tumors in the BENCHISTA StudyLaura Botta, Fabio Didonè, Angela Lopez-Cortes, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Journal of Clinical Medicine|January 21, 2022
Unraveling Bicuspid Aortic Valve Enigmas by Multimodality Imaging: Clinical ImplicationsArturo Evangelista Masip, Laura Galian-Gay, Andrea Guala, et al.
BMJ Open|June 15, 2019
Three contaminated sites in southern Italy. The Neonatal Environment and Health Outcomes cohort: protocol for a longitudinal birth cohort studySilvia Ruggieri, Gaspare Drago, Paolo Colombo, et al.
Iscience|August 18, 2025
A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancerShusuan Jiang, Ye Tian, Hongqian Guo, et al.
Pageof 8